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Abstract 
 
Flavopiridol is a promising therapeutic agent currently under phase I and phase II clinical investigation for the 
treatment of Chronic Lymphocytic Leukemia (CLL) and other hematologic and solid tumor malignancies. 
Flavopiridol is a potent inhibitor of CDks (cyclin-dependent kinases), and its cytotoxic activity is associated with 
the arrest of cells in G1 or G2 phases of the cell cycle.1 Breast cancer resistance protein (BCRP) is a 70 kDA 
transmembrane transporter involved in multidrug resistance.2 BCRP exports flavopiridol from cells3 resulting in 
decreased intracellular drug accumulation and resistance to its cytotoxic effects. A single nucleotide 
polymorphism in BCRP is known to change amino acid 141 from glutamine to lysine. To determine the effects 
on flavopiridol transport caused by this mutation, HEK-293 (human embryonic kidney) cells both stably and 
transiently transfected with wild-type and mutant BCRP were evaluated in flavopiridol cytotoxicity and transport 
assays. While early differences were observed in cytotoxicity assays with cells stably transfected with empty 
vector and BCRP, significant differences have not been observed with transiently transfected cells. In addition, 
no differences between the wild type and Q141K mutant were observed in both cytotoxicity assays comparing 
IC50 values and transport assays measuring the amount of intracellular flavopiridol. This report summarizes 
early efforts to develop the methods for evaluating the effects of the Q141K mutant. Further work to clarify the 
impact of this mutation on BCRP transport of flavopiridol is ongoing. 
 
 
 
Introduction 
 
CLL is the most common form of leukemia 
in western countries.4 The disease is characterized 
by the clonal proliferation and accumulation of 
neoplastic B lymphocytes in the blood, bone 
marrow, lymph nodes, and spleen.5 Approximately 
15,500 new cases were diagnosed in 2007,6 and 
4,500 men and women will die from the disease 
each year7. With an average age of incidence at 62 
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years, CLL is an adult disease and only 10-15% of 
cases are people below 50 years of age.4 At 
present, there is no curative therapy for CLL.5 
Flavopirdol is a therapeutic agent currently 
in clinical trials for the treatment of hematological 
malignancies such as CLL. Recently, flavopiridol 
was shown to be active in CLL patients with a 
response rate of approximately 50%.8 Flavopiridol 
is a potent inhibitor of CDks (cyclin-dependent 
kinases) which are involved in the regulation of the 
cell cycle. CDks are attractive targets for anti-
cancer treatment because their interruption causes 
cell cycle arrest  in either the G1 or G2 phase thus 
preventing mitosis and eventually leading to cell 
death.1 Flavopiridol induces cell death by down-
regulation of the anti-apoptotic proteins Mcl-1 and 
X-linked inactivator of apoptosis (XIAP)9,10,11 
through a p53-independent pathway12,13. 
Interestingly, CLL cells are non-dividing, but they 
maintain a high susceptibility to flavopiridol-induced 
cell death. 
Flavopiridol is administered intravenously, 
and elimination occurs mainly by metabolism and 
biliary excretion. Metabolism takes place primarily 
through glucuronidation by the uridine diphosphate-
glucuronosyltransferase (UGT) isoforms, UGT1A1 
and UGT1A9. Glucuronide metabolites and parent 
drug are believed to be excreted into bile via the 
transporters BCRP and MRP2, ATP-binding 
cassette transporters with diverse substrate 
specificity.14,15,16,17 Figure 2 displays a schematic of 
the hepatic/biliary elimination pathway, including 
transporters responsible for uptake and efflux.  
BCRP is a 70 kDA transmembrane 
transporter that facilitates multidrug resistance.2 
BCRP exports flavopiridol from cells3 resulting in 
decreased intracellular accumulation thereby 
providing a drug resistance mechanism. A single 
nucleotide polymorphism in BCRP is known to 
change amino acid 141 from glutamine to lysine. As 
a potential contributor of differential response to 
flavopiridol, genetic differences in BCRP may result 
in altered flavopiridol disposition and patient 
response. To determine the effects on flavopiridol 
transport caused by this mutation, HEK-293 
(human embryonic kidney) cells both stably and 
transiently transfected were exposed to flavopiridol 
and analyzed using cytotoxicity and 
Figure 2: Flavopiridol Clearance and the Role of Transporters 
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transport/uptake assays. 
Herein, efforts to evaluate the effects of the 
Q141K mutation on BCRP-mediated transport and 
resistance to the cytotoxic effects of flavopiridol are 
described. 
 
   
 
Materials and Methods    
 
  
Compounds 
 
Flavopiridol (NSC 649890, HMR 1275, Alvocidib, 
MW 401.84) was obtained from the NCI as a 
hydrochloride salt with MW 438.29. The internal 
standard (IS), genistein (MW 270.24) was obtained 
from Sigma (St. Louis, MO), and SN-38 was 
purchased from LKT Laboratories (St. Paul, MN). 
All other chemicals were obtained from 
ThermoFisher Scientific (St. Louis, MO) unless 
otherwise noted. 
 
 
Cell Culture 
 
HEK-293 cells were grown in RPMI 1640 medium 
supplemented with 10% fetal bovine serum and 
~1% L-glutamine at 37°C with 5% CO2. To maintain 
expression in the cells stably transfected with either 
BCRP or pcDNA3 empty vector, G418 was added 
to the medium at a concentration of 1mg/ml. Cells 
stably transfected with BCRP and pcDNA3 and 
BCRP and Q141K vectors were donated for this 
project by Dr. Duxin Sun. 
 
 
Plasmid DNA Transfections 
 
The transfection of empty pcDNA3, wild-type and 
Q141K mutant plasmids into HEK-293 cells was 
performed using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) transfection reagent. One day prior 
to transfections, cells were seeded into a T-25 flask 
so that they would be ~90% confluent the following 
day. The DNA plasmids were diluted to 8,000 
ng/flask in Opti-MEM I Reduced Serum Medium 
(Invitrogen), and Lipofectamine 2000 was diluted 
according to manufacturer’s instructions. The 
diluted DNA and diluted Lipofectamine 2000 were 
combined, incubated for 20 minutes at room 
temperature then added to the T-25 flask 
containing cells and medium. The flasks were 
incubated at 37°C with 5% CO2 for 24 hours prior to 
use. 
 
 
Western Blot Analysis 
 
Protein for the Western Blot analysis was isolated 
using cell lysis buffer (20 mM Tris pH 7.5, 150 mM 
NaCl, 1mM Na2EDTA, and 1% Triton X-100). The 
protein was diluted with 2X loading buffer so that 30 
ug of protein was loaded per well into a 10% SDS-
PAGE gel. The gel was subjected to 
electrophoresis at 120 V for 90 minutes at room 
temperature. The gel was then electrotransferred 
onto a Trans-Blot® (Bio-Rad, Hercules, CA) pure 
nitrocellulose membrane. The membrane was 
blocked with 5% nonfat dry milk in TBST and 
subsequently washed with TBST. Anti-BCRP mAb, 
clone BXP-21 (mouse IgG) was added for overnight 
incubation at 4°C with shaking. The membrane was 
washed again with TBST and then incubated with 
2° mouse antibody (Ab) for 1 hour at room 
temperature on a shaker. The membrane had a 
final wash with TBST followed by detection with 
either the chemiluminescence (Amersham, 
Buckinghamshire, UK) or chromogenic (Vector 
Laboratories, Burlingame, CA) method. 
 
 
Real-Time PCR 
 
Extraction of mRNA was obtained using Trizol 
(Invitrogen) reagent. Cells were seeded in 24-well 
plates at a density of 1.0 x 105 cells per well in 
complete RPMI 1640 medium and allowed to 
incubate for 24 hours at 37°C with 5% CO2. The 
media from each well was removed and replaced 
with 200 uL of Trizol reagent. The cell lysate was 
passed several times through a pipette tip with 
scrapping and transferred to a 1.5 mL centrifuge 
tube. The tube was centrifuged at 12,000xg for 10 
minutes at 6°C and the resulting cleared 
homogenate solution was transferred to a new 1.5 
mL centrifuge tube leaving behind the insoluble 
material. Subsequently, phase separation was 
achieved using 40 uL of chloroform per tube and 
the upper aqueous phase was transferred to a 
fresh 1.5 mL centrifuge tube. The RNA was 
precipitated by adding 100 uL of isopropyl alcohol 
to each tube. The tube was centrifuged at 8,000xg 
for 10 minutes at 6°C followed by removal of the 
supernatant, and washing of the RNA pellet with 
200 uL of 75% ethanol. The tube was allowed to 
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air-dry for 10 minutes and the RNA was redissolved 
with 10 uL of Rnase-free water. Real-time, one-step 
RT-PCR for mRNA of BCRP was performed using 
the Power SYBR Green RNA-to-CTTM 1-Step Kit 
(Applied Biosystems, Foster City, CA) protocol. 
Analysis of the data obtained from the experiment 
was performed using the method described by 
Livak KJ and Schmittgen TD18. RT-PCR was 
performed in the CCC Nucleic Acids Shared 
Resource. 
 
 
Cytotoxicity Assays 
 
Cytotoxicity assays were performed 
following the sulforhodamine B (SRB) assay 
procedure using the known BCRP substrate, SN-
38, as a positive cytotoxic control agent. Cells were 
seeded in 96-well plates at a density of 20,000 cells 
per well for the stably transfected cells, and 40,000 
cells per well for the transiently transfected cells. 
The cells were allowed to attach for 24 hours at 
37°C with 5% CO2. Either flavopiridol or SN-38 
dosing solutions were prepared in RPMI 1640 
medium without serum and were added to the cells 
at various concentrations (30-10,000 nM for 
flavopiridol and 1-1,000 nM for SN38), followed by 
incubation for 96 hours at 37°C with 5% CO2. 
Subsequently, the cells were fixed in 4°C 10% 
trichloroacetic acid, then stained in 0.4% 
sulforhodamine B dissolved in 1% acetic acid. After 
20 minutes at room temperature, the plates were 
washed with 1% acetic acid in H2O and allowed to 
dry overnight in a fume hood. The bound dye was 
solubilized with 10mM Tris base and cell density 
was determined by measuring the absorbance at 
540 nm. To investigate the Q141K mutant, PC-HEK 
(HEK-293 cells stably transfected with an empty 
vector) cells were established as the control. The 
flavopiridol IC50 value of PC-HEK was compared 
with those of R2-HEK (HEK-293 cells stably 
transfected with wild-type BCRP) cells, BCRP 
(HEK-293 cells transiently transfected with wild-
type BCRP) cells, and Q141K (HEK-293 cells 
transiently transfected with mutant BCRP) cells. 
 
 
Transport Assays 
 
Stably transfected and transiently 
transfected cells were seeded in 24-well plates at a 
density of 1.0 x 105 cells per well in complete RPMI 
1640 medium and allowed to incubate for 24 hours 
at 37°C with 5% CO2. Dosing solutions were 
prepared in RPMI 1640 medium without serum and 
L-glutamine at a concentration of 1 uM for 
flavopiridol and 10 uM for SN-38. The media from 
each well was removed and replaced with dosing 
solution for 10 minutes. The dosing solution was 
removed and the wells were washed with 4°C 
versene. To each well, 50 uL of Trypsin-EDTA was 
added then plates were incubated for 10 minutes at 
37°C. Afterwards, 300 uL of versene was added to 
each well, and the cells were resuspended. For 
each well, 150 uL was reserved to conduct the BCA 
Protein assay, and 200 uL was transferred to a 1.5 
mL centrifuge tube. Added to each 1.5 mL 
centrifuge tube were 1 mL of 4°C ACN and 200 nM 
of Genistein, the internal standard. The tubes were 
vortexed and centrifuged at 16,000xg for 10 
minutes. From each tube, 1 mL was removed and 
placed in a new 1.5 mL centrifuge tube. The tubes 
were dried in a speedvac. For each tube containing 
the dried sample, 150 uL of 95% H2O, 5% ACN, 
0.1% acetic acid was added, vortexed, and 
centrifuged at 16,000xg for 10 minutes. From each 
tube, 80 uL was removed and placed in an 
autosampler vial to be analyzed using LC/MS with 
a validated assay described by Phelps MA and 
Rozewski DM19. Once again SN-38 was used as 
the positive control. The data generated was 
compiled to determine if the Q141K mutant caused 
a change in the amount of intracellular flavopiridol. 
 
 
 
Results 
 
 
Real-Time PCR 
 
RT-PCR measuring RNA levels confirmed 
expression of ABCG2, the gene that codes for the 
BCRP transporter. From the data obtained, Table1 
shows that there is no difference seen between the 
PC-HEK control cells and the HEK-293 cells that do 
not contain the gene as expected. However, a 
significant difference of ΔΔCT is seen in gene 
expression between the PC-HEK control cells and 
the transiently transfected BCRP and Q141K cells, 
respectively (n=6). This suggests that the DNA 
plasmid vectors have been successfully transfected 
into the HEK-293 cells, and gene transcription is 
occurring. 
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Table 1: Relative Expression of ABCG2 to PC-HEK  
 
 
 
 
The results in ΔΔCT for HEK, BCRP, and Q141K indicate the relative 
change in gene expression of the ABCG2 gene to the reference group, 
PC, which does not contain the gene. 
 
Western Blot Analysis 
 
Western Blot analysis was used to 
determine level of protein expression. Results from 
this analysis are inconclusive since equivalent 
signals are observed in BCRP transfected and 
control (empty vector transfected) cells. There is 
evidence that a protein with MW ~70 kDA is 
present, but that protein is also observed in control 
samples. This can be seen in Figure 3 with the 
chromogenic detection method where a band is 
seen at ~70 kDA for the empty vector control, wild-
type BCRP, and mutant Q141K transfections. From 
these results, the protein detected is likely not 
BCRP but rather a random protein recognized by 
our antibody. Further work is required to develop 
the Western conditions. 
Figure 3: Western Blot Analysis Using Different Detection Methods 
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Cytotoxicity Assays 
 
Cytotoxicity assays were performed to 
evaluate the effects caused from the Q141K 
mutation on both flavopiridol and SN-38 cytotoxicity 
when compared to the wild-type BCRP. Table 2 
shows that when cells were transfected with either 
the wild-type or mutant BCRP transporter, the IC50 
values showed a slight increase suggesting that the 
transporter is eliminating drug from the cells. The 
results were consistent in that both transfections 
caused an increase in the amount of drug it takes 
to kill the cells, but there is no difference observed 
between the wild-type and mutant. Figure 4A 
shows a representative dose response curve for  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HEK cells treated with flavopiridol. Figure 4B shows 
a representative dose response curve from BCRP 
transiently transfected cells treated with flavopiridol. 
In figure 4B, a baseline level of cells remains even 
at higher doses of drug, indicating a higher 
tolerance for flavopiridol. This suggests that there 
could be two populations of cells in the studies with 
transiently transfected cells. One population is of 
the cells that are not expressing BCRP and are 
dying at low drug concentrations. The other 
population is that of cells expressing BCRP which 
have an apparently higher tolerance for drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Flavopiridol Resistance in Transiently Transfected Cell Lines 
Numbers represent ratio of IC50 of BCRP-transfected vs. control 
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Figure 4A: Dose Response Curve of Stably Transfected PC-HEK Cells Treated with Flavopiridol (nM) 
Figure 4B: Dose Response Curve of Transiently Transfected BCRP Cells Treated with Flavopiridol (nM) 
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Transport Assays 
 
The Transport assays provided data which 
agrees with the trend seen in cytotoxicity assays. 
Based on the transport velocity, BCRP acts to 
eliminate drug from cells, but there is no difference 
seen in the rate of drug elimination between the 
wild-type BCRP and mutant Q141K transporter. 
Figure 5 indicates that the intracellular flavopiridol 
transport velocity in pmol/min are approximately the 
 
 
 
 
 
 
 
 
 
 
 
same for the wild-type BCRP and mutant Q141K 
transporter. In Figure 6 using SN-38 as the positive 
control, the trend in relative transport velocity rate is 
again illustrated, although to a lesser degree. In 
both figures, wild-type BCRP and mutant Q141K 
are seen behaving very similarly in the rate of drug 
elimination. However, none of the trends observed 
are statistically significant. 
 
 
 
 
 
 
 
 
 
Figure 5: Flavopiridol Upatke in Transfected HEK-293 Cells (1uM, 10 min., n=5). 
     Numbers represent P values compared to PC-HEK 
Figure 6: SN-38 Uptake in Transfected HEK-293 Cells (10uM, 10 min., n=5). 
     Numbers represent P values compared to PC-HEK 
0
0.5
1
1.5
2
2.5
3
3.5
PC BCRP Q141K
Transfection
P = 0.13 P = 0.01
0
2
4
6
8
10
12
14
16
PC BCRP Q141K
Transfection
P = 0.26 P = 0.16
 
 
 
 
 9 
 
Discussion 
 
RT-PCR experiments were successful in 
revealing transcription of the ABCG2 gene, but it 
was not able to confirm that BCRP was being 
translated. To detect the presence of BCRP, the 
use of Western blots was attempted. These 
experiments were not successful due to apparently 
low recovery of the membrane transport proteins 
from the cell lysates. Additional experiments were 
planned to use a stronger cell lysis buffer (SDS and 
urea) for better solubilization of membrane proteins, 
and these experiments are in progress. 
 Both cytotoxicity assays and transport 
assays indicate small differences in mean uptake 
IC50 and velocity, respectively, between cells that 
contain BCRP and cells that do not. The difference 
seen however is not statistically significant, and 
indicates a need to improve the assays. This will be 
done with stably transfected cells with high levels of 
protein expression. Although some cells stably 
transfected with BCRP were donated for this 
project, these were not used at all times during the 
project due to the difficulty of recovering them from 
their frozen state in liquid nitrogen and the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
difficulty in maintaining healthy passages.  
 Even though the results in these studies 
indicate trends for reduced cytotoxicity and 
increased transport between BCRP or Q141K 
transfected vs. controls, the differences are small 
and statistically not significant. This is true for both 
SN-38 and flavopridol, which are both known 
substrates for BCRP. Additionally, no differences in 
cytotoxicity or transport between BCRP and the 
Q141K mutant are seen. Further work is ongoing to 
improve the results obtained to date. This work 
includes evaluation of different conditions for 
Western Blot analysis, and development of stably 
transfected cell lines overexpressing BCRP and 
Q141K mutant. 
Further experiments using techniques that 
this project has helped to develop may yield 
stronger evidence to support the results of this 
project. As flavopiridol continues through clinical 
trials, information that is generated about the drug 
from this and other studies become important due 
to the potential direct impact on treatment outcome. 
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